Quizartinib, an FLT3 inhibitor frequently mutated in AML, induces the quiescence of normal murine multipotent progenitors conferring a significant protection to mice treated with chemotherapy without affecting the elimination of FLT3-independent tumours by cytotoxic drugs [107]. This evidence concerns the gene FLT3 and neoplasm.